MedPath

Comparing Two Ways to Manage Head and Neck Lymphedema

Not Applicable
Recruiting
Conditions
Lymphedema
Head and Neck Cancer
Interventions
Other: Clinic-based CDT
Other: Home-based (a hybrid model) CDT
Registration Number
NCT05182229
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Brief Summary

This randomized clinical trial aims to compare clinic-based CDT and home-based (a hybrid model) CDT on changes in the severity of lymphedema, symptom burden, functional status, and healthcare utilization in HNC survivors with lymphedema.

Detailed Description

Primary aim: To compare the effects of clinic-based and home-based (a hybrid model) CDT on changes in the severity of lymphedema.

Secondary aim: To compare the effects of clinic-based and home-based (a hybrid model) CDT on symptom burden and functional status.

Exploratory aim: To compare the healthcare utilization between patients receiving clinic-based versus home-based (a hybrid model) CDT

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • >18 years of age
  • <=24 months post-HNC treatment
  • Diagnosis of head and neck lymphedema and referral by their oncology providers
  • Able to perform self-manual lymphatic drainage
  • Having an electronic device (a computer, tablet, iPad, laptop, or smartphone) and internet access at home
Exclusion Criteria
  • Active infection in soft tissues in the head and neck region
  • History of moderate or severe carotid artery occlusion
  • Significantly severe lymphedema (e.g., severe periorbital swelling)
  • Conditions impacting the safe delivery of lymphedema therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Clinic-Based Lymphedema TherapyClinic-based CDT-
Home-Based (a hybrid model) Lymphedema TherapyHome-based (a hybrid model) CDT-
Primary Outcome Measures
NameTimeMethod
Changes in severity of lymphedemaBaseline, Immediately after End of Intervention (an average of 6 weeks), 6-Month Post-Intervention, 12-Month Post-Intervention

Compare the effects of clinic-based and home-based CDT on changes in the severity of lymphedema. This outcome measure will be assessed via Head and Neck - External Lymphedema and Fibrosis Assessment Criteria (HN-LEF Assessment Criteria).

Secondary Outcome Measures
NameTimeMethod
Changes in degrees of jaw range of motionBaseline, Immediately after End of Intervention (an average of 6 weeks), 6-Month Post-Intervention, 12-Month Post-Intervention

Compare the effects of clinic-based and home-based CDT on jaw range of motion. Jaw range of motion will be measured via Jaw Range of Motion Scale.

Changes in degrees of cervical range of motionBaseline, Immediately after End of Intervention (an average of 6 weeks), 6-Month Post-Intervention, 12-Month Post-Intervention

Compare the effects of clinic-based and home-based CDT on cervical range of motion. Cervical Range of Motion will be measured via Cervical Range of Motion Instrument.

Changes in severity of symptom burdenBaseline, Immediately after End of Intervention (an average of 6 weeks), 6-Month Post-Intervention, 12-Month Post-Intervention

Compare the effects of clinic-based and home-based CDT on changes in the severity of symptom burden. This outcome measure will be assessed via Head and Neck - Lymphedema and Fibrosis Symptom Inventory (HN-LEF Symptom Inventory)

Trial Locations

Locations (6)

Jefferson Cherry Hospital Jefferson Health

🇺🇸

Cherry Hill, New Jersey, United States

Jefferson Torresdale Hospital Jefferson Health

🇺🇸

Philadelphia, Pennsylvania, United States

Asplundh Cancer Pavilion Jefferson Health

🇺🇸

Willow Grove, Pennsylvania, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Jefferson Health

🇺🇸

Philadelphia, Pennsylvania, United States

Temple University Hospital and Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath